Tramadol ANDAs are “approvable”
Teva, Apotex and Watson generics of J&J's Ultram (tramadol) are "approvable" at FDA while the agency resolves whether patent-protected sections of Ultram labeling are essential for safety and efficacy of the pain relief agent. In a November citizen petition, Apotex argued that the titration dosing schedules added to labeling were not prompted by safety or efficacy concerns (1"The Pink Sheet" Nov. 19, 2001, p. 14). Par also has an ANDA pending...
You may also be interested in...
Apotex' citizen petition requesting approval of generic Ultram argues that Johnson & Johnson did not make labeling changes for safety or efficacy reasons
Sandoz sees key opportunities ahead in both the US and Canadian biosimilars markets, the firm’s US vice-president for marketing, market access and patient services, Sheila Frame, tells Generics Bulletin in the second part of an exclusive interview.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.